Thirty years after prisoners with disabilities sued the state of California and 25 years after a federal court first ordered accommodations, a judge found that state prison and parole officials still are not doing enough to help deaf and blind prisoners — in part because they are not using readily available technology such as video recordings and laptop computers.
FDA grants RMAT designation to Poseida’s P-BCMA-ALLO1
P-BCMA-ALLO1 is licensed to Roche for the treatment of relapsed/refractory multiple myeloma. Credit: SkazovD/Shutterstock. Poseida Therapeutics has received the Regenerative Medicine Advanced Therapy (RMAT) designation